Janux Therapeutics, Inc. (JANX)
18.15
+0.33
(+1.85%)
USD |
NASDAQ |
Nov 04, 15:40
Janux Therapeutics EPS Diluted (Quarterly) : -0.3491 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3491 |
| March 31, 2026 | -0.3888 |
| December 31, 2025 | -0.514 |
| September 30, 2025 | -0.392 |
| June 30, 2025 | -0.547 |
| March 31, 2025 | -0.3804 |
| December 31, 2024 | -0.3557 |
| September 30, 2024 | -0.5136 |
| June 30, 2024 | -0.1094 |
| March 31, 2024 | -0.3009 |
| December 31, 2023 | -0.2519 |
| September 30, 2023 | -0.2531 |
| June 30, 2023 | -0.4185 |
| Date | Value |
|---|---|
| March 31, 2023 | -0.418 |
| December 31, 2022 | -0.3863 |
| September 30, 2022 | -0.4021 |
| June 30, 2022 | -0.4074 |
| March 31, 2022 | -0.3246 |
| December 31, 2021 | -0.3253 |
| September 30, 2021 | -0.2615 |
| June 30, 2021 | -0.151 |
| March 31, 2021 | -0.0549 |
| December 31, 2020 | -0.0398 |
| September 30, 2020 | -0.0306 |
| June 30, 2020 | -0.0599 |
| March 31, 2020 | -0.034 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Iovance Biotherapeutics, Inc. | -0.1051 |
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -21.97M |
| Revenue (Quarterly) | 10.27M |
| Total Expenses (Quarterly) | 32.24M |
| Enterprise Value | 138.49M |
| Gross Profit Margin (Quarterly) | 95.49% |
| Profit Margin (Quarterly) | -214.0% |
| Earnings Yield | -9.06% |
| Normalized Earnings Yield | -9.057 |